Author
Listed:
- Ifat Geron
(Tel Aviv University
Chaim Sheba Medical Center
The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel)
- Angela Maria Savino
(Tel Aviv University
Chaim Sheba Medical Center
The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel)
- Hila Fishman
(Tel Aviv University
Chaim Sheba Medical Center
The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel)
- Noa Tal
(Tel Aviv University
Chaim Sheba Medical Center)
- John Brown
(UCL Cancer Institute, UCL)
- Virginia A. Turati
(UCL Cancer Institute, UCL)
- Chela James
(UCL Cancer Institute, UCL)
- Jolanda Sarno
(Stanford University)
- Michal Hameiri-Grossman
(The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel)
- Yu Nee Lee
(Tel Aviv University
Edmond and Lily Safra Children’s Hospital Sheba Medical Center)
- Avigail Rein
(Tel Aviv University
Chaim Sheba Medical Center
The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel)
- Hillary Maniriho
(Tel Aviv University
The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel)
- Yehudit Birger
(Tel Aviv University
Chaim Sheba Medical Center
The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel)
- Anna Zemlyansky
(The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel)
- Inna Muler
(Chaim Sheba Medical Center)
- Kara L. Davis
(Stanford University)
- Victoria Marcu-Malina
(Chaim Sheba Medical Center Tel Hashomer)
- Nicole Mattson
(City of Hope Comprehensive Cancer Center)
- Oren Parnas
(Hebrew University Faculty of Medicine)
- Rabea Wagener
(Heinrich-Heine-University Düsseldorf)
- Ute Fischer
(Heinrich-Heine-University Düsseldorf)
- João T. Barata
(Universidade de Lisboa)
- Catriona H. M. Jamieson
(Department of Medicine and Sanford Stem Cell Clinical Center)
- Markus Müschen
(City of Hope Comprehensive Cancer Center)
- Chun-Wei Chen
(City of Hope Comprehensive Cancer Center)
- Arndt Borkhardt
(Heinrich-Heine-University Düsseldorf)
- Ilan Richard Kirsch
(Adaptive Biotechnologies, Inc.)
- Arnon Nagler
(Tel Aviv University
Hematology Division BMT and Cord Blood Bank Chaim Sheba Medical Center Tel-Hashomer)
- Tariq Enver
(UCL Cancer Institute, UCL)
- Shai Izraeli
(Tel Aviv University
Chaim Sheba Medical Center
The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children’s Medical Center of Israel
City of Hope Comprehensive Cancer Center)
Abstract
Kinase signaling fuels growth of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Yet its role in leukemia initiation is unclear and has not been shown in primary human hematopoietic cells. We previously described activating mutations in interleukin-7 receptor alpha (IL7RA) in poor-prognosis “ph-like” BCP-ALL. Here we show that expression of activated mutant IL7RA in human CD34+ hematopoietic stem and progenitor cells induces a preleukemic state in transplanted immunodeficient NOD/LtSz-scid IL2Rγnull mice, characterized by persistence of self-renewing Pro-B cells with non-productive V(D)J gene rearrangements. Preleukemic CD34+CD10highCD19+ cells evolve into BCP-ALL with spontaneously acquired Cyclin Dependent Kinase Inhibitor 2 A (CDKN2A) deletions, as commonly observed in primary human BCP-ALL. CRISPR mediated gene silencing of CDKN2A in primary human CD34+ cells transduced with activated IL7RA results in robust development of BCP-ALLs in-vivo. Thus, we demonstrate that constitutive activation of IL7RA can initiate preleukemia in primary human hematopoietic progenitors and cooperates with CDKN2A silencing in progression into BCP-ALL.
Suggested Citation
Ifat Geron & Angela Maria Savino & Hila Fishman & Noa Tal & John Brown & Virginia A. Turati & Chela James & Jolanda Sarno & Michal Hameiri-Grossman & Yu Nee Lee & Avigail Rein & Hillary Maniriho & Yeh, 2022.
"An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia,"
Nature Communications, Nature, vol. 13(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28218-7
DOI: 10.1038/s41467-022-28218-7
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28218-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.